SOPHiA GENETICS raises USD $110 million to enter into the next stage of its expansion

02.10.2020 09:40, Isabelle Mitchell

SOPHiA GENETICS, global leader in data-driven medicine, announced the closing of a USD 110 million financing round to enter into the next stage of its expansion, with a focus on supporting the growing clinical and biopharma demand for data-driven medicine worldwide. SOPHiA GENETICS was one of the TOP 100 Swiss startups for four consecutive years (2012-2016), and it is one of the 25 most promising scale-ups in Switzerland. 

This Series F round was led by aMoon, a leading health-tech and life sciences venture fund based in Israel, and Hitachi Ventures, a venture arm of Japanese Hitachi Group. The company also received the trust of prime financial institutions Credit Suisse and the Pictet group. Existing investors Swisscom Ventures, Endeavour Vision, Generation Investment Management, Alychlo, and Eurazeo Growth participated in the round, as well as newcomers ACE & Company and Famille C Invest.

Having established the world’s largest data-driven medicine community network through its universal and collaborative AI platform, SOPHiA GENETICS supports healthcare professionals by translating multiple sources of complex medical data into valuable clinical insights. The SOPHiA Platform is used by over 1,000 healthcare institutions and has analyzed 600,000 genomic profiles, up to 17,000 new profiles a month. Through continual learning and network effects, experts worldwide are empowered to act with confidence for better patient management.

The new funding round will boost the company’s penetration in both the US and Asian markets. Proceeds will also be dedicated to increasing the platform’s multimodal capabilities and its adoption by healthcare institutions worldwide. Leveraging this momentum, SOPHiA GENETICS will be best positioned to power biopharma’s effort to optimize and accelerate the development of new targeted therapies. SOPHiA GENETICS was one of the TOP 100 Swiss startups for four consecutive years (2012-2016), and it is one of the 25 most promising scale-ups in Switzerland. 
 
“Since inception, we knew that leveraging a wide range of data modalities powered by cutting-edge technologies was key to sustainably deliver better outcomes to the global healthcare community,” concluded Jurgi Camblong, CEO and Founder at SOPHiA GENETICS. “Now, with this new funding round, we can embark on the next stage of our development and take our collaborative approach further, delivering intelligent medicine, together.”

As SOPHiA enters this new phase of rapid expansion, Didier Hirsch, former CFO at Agilent, joins the company’s Board of Directors. He will also chair the company’s Audit Committee, ushering SOPHiA GENETICS toward its next important milestones.

“SOPHiA has established an impressive track record of disrupting healthcare and enabling a decentralized approach. This new funding round will further strengthen SOPHiA’s already unique offering, performance, and life-changing impact on patients and targeted therapies,” said Troy Cox, Chairman of the Board of Directors of SOPHiA GENETICS.